481 related articles for article (PubMed ID: 7690680)
41. Prethrombotic state due to hypercoagulability in patients with permanent transvenous pacemakers.
Ito T; Tanouchi J; Kato J; Nishino M; Iwai K; Tanahashi H; Hori M; Yamada Y; Kamada T
Angiology; 1997 Oct; 48(10):901-6. PubMed ID: 9342969
[TBL] [Abstract][Full Text] [Related]
42. Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders.
Takahashi H; Tatewaki W; Wada K; Hanano M; Shibata A
Am J Hematol; 1990 Feb; 33(2):90-5. PubMed ID: 1689102
[TBL] [Abstract][Full Text] [Related]
43. [Hemostatic abnormalities of the patients with cancer. Clinical significance and fibrinolytic properties of the cancer tissues].
Sato M
Nihon Geka Gakkai Zasshi; 1983 Jun; 84(6):471-87. PubMed ID: 6201715
[TBL] [Abstract][Full Text] [Related]
44. Hemostatic molecular markers before the onset of disseminated intravascular coagulation.
Wada H; Sakuragawa N; Mori Y; Takagi M; Nakasaki T; Shimura M; Hiyoyama K; Nisikawa M; Gabazza EC; Deguchi K; Kazama M; Shiku H
Am J Hematol; 1999 Apr; 60(4):273-8. PubMed ID: 10203100
[TBL] [Abstract][Full Text] [Related]
45. Markers of activated hemostasis and fibrinolysis in patients with pulmonary malignancies: comparison of plasma levels in central venous and pulmonary venous blood.
Kalweit GA; Feindt P; Micek M; Gams E; Hellstern P
Thromb Res; 2000 Feb; 97(3):105-11. PubMed ID: 10680641
[TBL] [Abstract][Full Text] [Related]
46. Diagnostic and Prognostic Value of TAT, PIC, TM, and t-PAIC in Malignant Tumor Patients With Venous Thrombosis.
Zhou K; Zhang J; Zheng ZR; Zhou YZ; Zhou X; Wang LD; Suo B; Jiang XF; Liu PJ; Wang DH
Clin Appl Thromb Hemost; 2020; 26():1076029620971041. PubMed ID: 33141604
[TBL] [Abstract][Full Text] [Related]
47. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment.
Tomura S; Nakamura Y; Deguchi F; Ando R; Chida Y; Marumo F
Thromb Res; 1991 Oct; 64(1):81-90. PubMed ID: 1776141
[TBL] [Abstract][Full Text] [Related]
48. Alteration of coagulation and fibrinolysis systems after multidrug anticancer therapy for lung cancer.
Gabazza EC; Taguchi O; Yamakami T; Machishi M; Ibata H; Suzuki S; Shima T
Eur J Cancer; 1994; 30A(9):1276-81. PubMed ID: 7999412
[TBL] [Abstract][Full Text] [Related]
49. Activation of blood coagulation and fibrinolysis in diabetes mellitus: evaluation by plasma levels of thrombin-antithrombin III complex and plasmin-alpha 2-plasmin inhibitor complex.
Takahashi H; Tsuda A; Tatewaki W; Wada K; Niwano H; Shibata A
Thromb Res; 1989 Sep; 55(6):727-35. PubMed ID: 2528845
[TBL] [Abstract][Full Text] [Related]
50. Abnormalities of blood coagulation and fibrinolysis in psoriasis.
Marongiu F; Sorano GG; Bibbò C; Pistis MP; Conti M; Mulas P; Balestrieri A; Biggio P
Dermatology; 1994; 189(1):32-7. PubMed ID: 7516205
[TBL] [Abstract][Full Text] [Related]
51. The proteinase inhibitor complexes (antithrombin III-thrombin, alpha 2antiplasmin-plasmin and alpha 1antitrypsin-elastase) in septicemia, fulminant hepatic failure and cardiac shock: value for diagnosis and therapy control in DIC/F syndrome.
Egbring R; Seitz R; Blanke H; Leititis J; Kesper HJ; Burghard R; Fuchs G; Lerch L
Behring Inst Mitt; 1986 Feb; (79):87-103. PubMed ID: 2424425
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic Strategies for Disseminated Intravascular Coagulation Associated with Aortic Aneurysm.
Yamada S; Asakura H
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163216
[TBL] [Abstract][Full Text] [Related]
53. [The changes of coagulation and fibrinolysis function on hypoxia adaptation mechanism].
Cui JH; Zhang XZ; Xie YZ; Zhou XM; Ha ZD
Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2001 Nov; 17(4):363-5. PubMed ID: 21207702
[TBL] [Abstract][Full Text] [Related]
54. Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication.
Tohgi H; Takahashi H; Chiba K; Tamura K
Stroke; 1993 Jun; 24(6):801-4. PubMed ID: 8506551
[TBL] [Abstract][Full Text] [Related]
55. [Changes in the activation markers of blood coagulation and fibrinolysis in the neonatal period].
Ries M; Klinge J; Rauch R; Zenker M; Aydin I; Harms D
Klin Padiatr; 1996; 208(6):350-4. PubMed ID: 9064377
[TBL] [Abstract][Full Text] [Related]
56. [Dynamics of blood coagulation and fibrinolysis and laboratory findings in disseminated intravascular coagulation].
Madoiwa S
Rinsho Ketsueki; 2010 Jan; 51(1):20-8. PubMed ID: 20134136
[No Abstract] [Full Text] [Related]
57. Serum antithrombin III and alpha-2-antiplasmin concentration in patients with lung carcinoma.
Dabrowska M; Prokopowicz J; Kemona H; Kretowska J; Kulik S; Głuszczak M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1988; 115(5):641-6. PubMed ID: 2465244
[TBL] [Abstract][Full Text] [Related]
58. Recombinant hirudin for the treatment of disseminated intravascular coagulation in patients with haematological malignancy.
Saito M; Asakura H; Jokaji H; Uotani C; Kumabashiri I; Morishita E; Yamazaki M; Aoshima K; Matsuda T
Blood Coagul Fibrinolysis; 1995 Feb; 6(1):60-4. PubMed ID: 7540878
[TBL] [Abstract][Full Text] [Related]
59. Coagulation/fibrinolysis balance and lung cancer.
van Wersch JW; Tjwa MK
Haemostasis; 1991; 21(2):117-23. PubMed ID: 1959797
[TBL] [Abstract][Full Text] [Related]
60. [Alteration of serum levels of endotoxin, polymorphonuclear leukocyte elastase, and the molecular markers of the coagulation and fibrinolytic system in the patients with esophageal cancer and lung cancer before and following operation].
Moriyama H; Hirata S; Kubo Y
Rinsho Byori; 1995 Mar; 43(3):233-7. PubMed ID: 7745828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
